65 related articles for article (PubMed ID: 20039040)
1. A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
Sabharwal A; Corrie PG; Midgley RS; Palmer C; Brady J; Mortimer P; Watson AJ; Margison GP; Middleton MR
Cancer Chemother Pharmacol; 2010 Oct; 66(5):829-35. PubMed ID: 20039040
[TBL] [Abstract][Full Text] [Related]
2. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Ranson M; Middleton MR; Bridgewater J; Lee SM; Dawson M; Jowle D; Halbert G; Waller S; McGrath H; Gumbrell L; McElhinney RS; Donnelly D; McMurry TB; Margison GP
Clin Cancer Res; 2006 Mar; 12(5):1577-84. PubMed ID: 16533784
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.
Saunders MP; Hogg M; Carrington B; Sjursen AM; Allen J; Beech J; Swindell R; Valle JW
Br J Cancer; 2004 Oct; 91(8):1447-52. PubMed ID: 15452550
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
[TBL] [Abstract][Full Text] [Related]
5. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
Price T; Hill M
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.
Khan OA; Ranson M; Michael M; Olver I; Levitt NC; Mortimer P; Watson AJ; Margison GP; Midgley R; Middleton MR
Br J Cancer; 2008 May; 98(10):1614-8. PubMed ID: 18475294
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
Takii Y; Yamazaki T; Okada T; Tani T; Funakoshi K; Maruyama S; Hasegawa J; Akazawa K; Hatakeyama K;
Chemotherapy; 2013; 59(5):338-43. PubMed ID: 24820531
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
Sadahiro S; Suzuki T; Maeda Y; Tanaka A; Ishikawa K; Makuuchi H; Murayama C
Oncology; 2009; 76(5):338-41. PubMed ID: 19307740
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
Tawbi HA; Villaruz L; Tarhini A; Moschos S; Sulecki M; Viverette F; Shipe-Spotloe J; Radkowski R; Kirkwood JM
Br J Cancer; 2011 Sep; 105(6):773-7. PubMed ID: 21811257
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
[TBL] [Abstract][Full Text] [Related]
12. Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.
Watson AJ; Sabharwal A; Thorncroft M; McGown G; Kerr R; Bojanic S; Soonawalla Z; King A; Miller A; Waller S; Leung H; Margison GP; Middleton MR
Clin Cancer Res; 2010 Jan; 16(2):743-9. PubMed ID: 20068091
[TBL] [Abstract][Full Text] [Related]
13. High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?
Ducreux M; Raoul JL; Marti P; Merrouche Y; Tigaud JM; Rebischung C; Boige V
Oncology; 2008; 74(1-2):17-24. PubMed ID: 18536526
[TBL] [Abstract][Full Text] [Related]
14. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of irinotecan and UFT for advanced or metastatic colorectal cancer.
Mibu R; Tanaka S; Futami K; Shimada K; Hotokezaka M; Nakahara S; Ichimiya H; Kido H; Hirano Y; Kashiwagi T; Eguchi T; Mitsuki K; Mizumoto K; Tanaka M
Anticancer Res; 2007; 27(4C):2673-7. PubMed ID: 17695431
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Meyerhardt JA; Clark JW; Supko JG; Eder JP; Ogino S; Stewart CF; D'Amato F; Dancey J; Enzinger PC; Zhu AX; Ryan DP; Earle CC; Mayer RJ; Michelini A; Kinsella K; Fuchs CS
Cancer Chemother Pharmacol; 2007 Oct; 60(5):661-70. PubMed ID: 17216531
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
Bajetta E; Beretta E; Di Bartolomeo M; Cortinovis D; Ferrario E; Dognini G; Toffolatti L; Buzzoni R
Oncology; 2004; 66(2):132-7. PubMed ID: 15138365
[TBL] [Abstract][Full Text] [Related]
18. Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
Chan E; Kwak EL; Hwang J; Heiskala M; de La Bourdonnaye G; Mita M
Cancer Chemother Pharmacol; 2015 Apr; 75(4):701-9. PubMed ID: 25627002
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM
Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959
[TBL] [Abstract][Full Text] [Related]
20. Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Bajetta E; Di Bartolomeo M; Buzzoni R; Ferrario E; Dotti KF; Mariani L; Bajetta R; Gevorgyan A; Venturino P; Galassi M
Cancer Chemother Pharmacol; 2009 Jun; 64(1):67-72. PubMed ID: 18936940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
